Synapse - Vincent Miller

Results (270)

Comprehensive genomic profiling of hematologic malignancies by a clinical next generation sequencing-based assay

Meeting Abstract

Ross, J. S.; Nahas, M.; Lipson, D.; Otto, G. A.; Yelensky, R.; Abdel-Wahab, O.; Wang, K.; He, J.; Intlekofer, A. M.; Rampal, R. K.; more...
Modern Pathology (2014)

Fulltext@MSK | Save

Comprehensive genomic profiling of hematologic malignancies by a clinical next generation sequencing-based assay

Meeting Abstract

Ross, J. S.; Nahas, M.; Lipson, D.; Otto, G. A.; Yelensky, R.; Abdel-Wahab, O.; Wang, K.; He, J.; Intlekofer, A. M.; Rampal, R. K.; more...
Laboratory Investigation (2014)

Fulltext@MSK | Save

ATLAS: Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer

Journal Article

Johnson, B. E.; Kabbinavar, F.; Fehrenbacher, L.; Hainsworth, J.; Kasubhai, S.; Kressel, B.; Lin, C. Y.; Marsland, T.; Patel, T.; Polikoff, J.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

Journal Article

Yu, H. A.; Arcila, M. E.; Rekhtman, N.; Sima, C. S.; Zakowski, M. F.; Pao, W.; Kris, M. G.; Miller, V. A.; Ladanyi, M.; Riely, G. J.
Clinical Cancer Research (2013)

Fulltext@MSK | Save

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

Journal Article

Yu, H. A.; Sima, C. S.; Huang, J.; Solomon, S. B.; Rimner, A.; Paik, P.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; more...
Journal of Thoracic Oncology (2013)

Fulltext@MSK | Save

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase iib/iii trial (lux-lung 1)

Journal Article

Hirsh, V.; Cadranel, J.; Cong, X. J.; Fairclough, D.; Finnern, H. W.; Lorence, R. M.; Miller, V. A.; Palmer, M.; Yang, J. C. H.
Journal of Thoracic Oncology (2013)

Fulltext@MSK | Save

Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

Meeting Abstract

Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs)

Meeting Abstract

Johnson, M. L.; Yu, H. A.; Hart, E. M.; Worden, R.; Rademaker, A.; Gupta, R.; Miller, C.; Patel, J. D.; Kris, M. G.; Miller, V. A.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer

Meeting Abstract

Ohashi, K.; Chmielecki, J.; Lin, Y. L.; Pan, H. L.; Vnencak-Jones, C.; Arcila, M.; Wang, L.; Fernandez, L.; Keisuke, A.; Shien, K.; more...
Cancer Research (2012)

Fulltext@MSK | Save

HER2 amplification: A potential mechanism of acquired resistance to egfr inhibition in EGFR -mutant lung cancers that lack the second-site EGFR T790M mutation

Journal Article

Takezawa, K.; Pirazzoli, V.; Arcila, M. E.; Nebhan, C. A.; Song, X.; de Stanchina, E.; Ohashi, K.; Janjigian, Y. Y.; Spitzler, P. J.; Melnick, M. A.; more...
Cancer Discovery (2012)

Fulltext@MSK | Save